FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS


Date/App# patent app List of recent Vaccine-related patents
12/11/14
20140364296
 Centrifuge vessels suitable for live cell processing and associated systems and methods patent thumbnailCentrifuge vessels suitable for live cell processing and associated systems and methods
Centrifuge vessels suitable for live cell processing include a bowl with a cap, and a tube inside the bowl extending between the cap and a lower portion of the bowl. The bottom of the bowl can have a closed annular ring surrounding a center mound.
12/11/14
20140363878
 Recombinant negative strand virus rna expression systems and vaccines patent thumbnailRecombinant negative strand virus rna expression systems and vaccines
The present invention relates to recombinant rna virus templates derived from and applicable to negative strand naturally non-segmented viruses, including the families bornaviridae, filoviridae, and paramyxoviridae, and methods for generating such recombinant rna virus templates, wherein the templates are generated from two or more recombinant rna molecules. The invention relates to the use of segmented recombinant rna virus templates for naturally non-segmented rna viruses to express heterologous gene products in appropriate host cell systems and/or to construct recombinant viruses taken from that family and that express, package, and/or present the heterologous gene product.
12/11/14
20140363494
 Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3) patent thumbnailPharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express egfr and gm3 n-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets.
12/11/14
20140363474
 Adjuvanted influenza virus compositions patent thumbnailAdjuvanted influenza virus compositions
The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant..
12/11/14
20140363469
 Viral attenuation and vaccine production patent thumbnailViral attenuation and vaccine production
The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microrna binding sites within the viral target sequence of the pathogen.. .
12/11/14
20140363468
 Combined influenza vaccines for seasonal and pandemic protection patent thumbnailCombined influenza vaccines for seasonal and pandemic protection
Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza a strains (h1n1 and h3n2) and one influenza b strain.
12/11/14
20140363466
 Method of treating pregnant cows and/or heifers patent thumbnailMethod of treating pregnant cows and/or heifers
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (bvdv) for the the prophylaxis and treatment of bvdv caused infections. The invention also relates to a method of vaccinating a pregnant cow..
12/11/14
20140363465
 Mycobacterial vaccine vectors and methods of using the same patent thumbnailMycobacterial vaccine vectors and methods of using the same
Mycobacterium bovis bcg is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are bcg strains that generate greater mhc class i presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's cd8+ t cell response against the transgenic protein following vaccination.
12/11/14
20140363461
 Adjuvanted formulations of staphylococcus aureus  antigens patent thumbnailAdjuvanted formulations of staphylococcus aureus antigens
The efficacy of s. Aureus vaccines can be enhanced by adjuvanting s.
12/11/14
20140363459
 Synthetic capsid proteins and uses thereof patent thumbnailSynthetic capsid proteins and uses thereof
The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic circovirus type capsid proteins with improved properties.
12/11/14
20140363456
Tumor-specific gm-csf cytokine response as predictor of cancer vaccine effectiveness
The present invention relates to methods of treating cancer with a cancer vaccine using granulocyte-macrophage colony-stimulating factor (gm-csf) as a biomarker; methods of prognosticating an outcome of cancer treatment with a cancer vaccine using gm-csf as a biomarker; methods for qualifying subjects for cancer vaccination using gm-csf as a biomarker; methods for comparing the efficacy of two or more cancer vaccine treatments based on gm-csf response; and kits for the effective treatment of cancer.. .
12/11/14
20140360214
Refrigeration apparatus
An apparatus for cooling objects such as food items, beverages or vaccines comprises at least two reservoirs, a cooling device for cooling fluid contained in one of the reservoirs and a thermal transfer region between respective upper regions of the reservoirs. The thermal transfer region permits thermal transfer between the fluid contained in the reservoirs such that cooling of the fluid in one reservoir causes cooling of the fluid in the other reservoir..
12/04/14
20140358576
System and method for surveillance and evaluation of safety risks associated with medical interventions
Certain embodiments described herein relate to systems and methods used to estimate safety-related risks associated with the use of medical products, treatments, and interventions (e.g., drugs, vaccines, medications, dietary supplements, and medical devices). More particularly, the present description relates to a method and system for estimating the risk (e.g., using a safety risk score, ranking, designation, estimate, or the like) associated with the use of an individual medical intervention..
12/04/14
20140357845
Influenza virus vaccines and uses thereof
The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin ha1 domain that comprises an ha1 n-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an ha1 c-terminal stem segment, and (b) an influenza hemagglutinin ha2 domain, wherein on or more amino acids in the ha2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza..
12/04/14
20140356962
Novel attenuated poliovirus: pv-1 mono-cre-x
A novel and stable attenuated poliovirus is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region (with inactivation of the native ere element located in the coding region of 2c (mono-crepv), and replacing the nucleic acid sequence of all or part of the capsid coding region (pi) with a substitute pi coding region having reduced codon pair bias. The stably attenuated poliovirus is effective for vaccines and immunization..
12/04/14
20140356415
Compositions and vaccines comprising vesicles and methods of using the same
The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens.
12/04/14
20140356396
Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
The invention describes a set of formulations and methods that provide for stabilization of viruses in liquid and dried states. In particular, formulations include rotavirus preparations with excess ca2+ and high viscosities that ensure infective potency at elevated temperatures.
12/04/14
20140356395
Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided..
11/27/14
20140350220
Novel surface exposed haemophilus influenzae protein (protein; pe)
The present invention relates to a surface exposed protein (protein e; pe), a virulence factor, which can be detected in haemophilus influenzae, having an amino acid sequence as described in seq id no: 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pe (a)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described.
11/27/14
20140350085
Novel sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro
This invention relates to a composition and its use for formulating nucleic acid-based drugs/vaccines with sugar alcohol compositions into complexes for both in-vitro and in-vivo delivery. Particularly, the present invention includes the ingredients and processes necessary for formulating therapeutic and pharmaceutical nucleic acid compositions, such as mirna, microrna precursors, shrnas, sirnas, ribozymes, antisense rnas/dnas, rna-dna hybrids and dna vectors/vaccines, with glycylated sugar alcohols/sugars into delivery complexes, which can then be absorbed by cells in vivo and in vitro via active endocytosis.
11/27/14
20140348875
Koi herpesvirus vaccine
The present invention relates to a recombinant koi herpesvirus (khv), methods for the production of such khv, cells comprising such khv and the use of such khv as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by koi herpesvirus in carp such as cyprinus carpio carpio or cyprinus carpio koi.. .
11/27/14
20140348868
Compositions comprising pneumococcal antigens
Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens.
11/20/14
20140341978
Cancer immunotherapy
We formulated multiple tlr agonists into gvax (lethally irradiated tumor cell vaccines engineered to secrete gm-csf). Specifically, gla and r848, tlr4 and tlr7/8 agonists found to be safe in patients, were formulated with gvax (tegvax—for tlr agonists enhanced gvax), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable b16.
11/20/14
20140341974
Liposomal vaccine adjuvants and methods of making and using same
A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (dppc), dipalmitoyl phosphatidylglycerol (dppg), dioleoyl phosphatidylcholine (dopc), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.. .
11/20/14
20140341970
Vaccine composition containing synthetic adjuvant
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
11/20/14
20140341950
Recombinant avian paramyxovirus vaccine and method for making and using thereof
The present invention encompasses engineered apmv compositions or vaccines. The vaccine or composition may be a recombinant apmv composition or vaccine.
11/20/14
20140341948
Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
In particular, the invention relates to attenuated influenza viruses having modifications to the ns1 gene that diminish or eliminate the ability of the ns1 gene product to antagonize the cellular ifn response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations..
11/20/14
20140341947
Immunogenic compositions comprising lawsonia intracellularis
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of ppe caused by l. Intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
11/20/14
20140341943
Ehrlichia ewingii proteins, nucleic acids, and methods of their use
The novel omp-1 gene cluster encoding twenty one ehrlichia ewingii (ee) proteins was isolated and sequenced completely. This invention relates to isolated e.
11/20/14
20140341941
Vaccines and methods for using the same
Improved anti-hiv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for hiv subtype a envelope protein, those having consensus sequences for hiv subtype b envelope protein, those having consensus sequences for hiv subtype c envelope protein, those having consensus sequences for hiv subtype d envelope protein, those having consensus sequences for hiv subtype b consensus nef-rev protein, and those having consensus sequences form hiv gag protein subtypes a, b, c and d.
11/20/14
20140339126
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, pediarix® (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant) and inactivated poliovirus vaccine), havrix® (hepatitis a vaccine), engerix-b® (hepatitis b vaccine (recombinant)), twinrix® (hepatitis a & hepatitis b (recombinant) vaccine), eperzan® (albiglutide), mage-a3 antigen-specific cancer immunotherapeutic (astuprotimut-r), gsk2402968 (drisapersen), and hz/su (herpes zoster vaccine)..
11/13/14
20140336366
Bioconjugate vaccines made in prokaryotic cells
Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions..
11/13/14
20140336358
Methods and compositions for tumor vaccination and therapy
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. A cdr-2 antigen, hud antigen.
11/13/14
20140336225
Kinase modulators for the treatment of cancer
Compounds of the substituted pyrazole class as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases.
11/13/14
20140336175
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..
11/13/14
20140335128
Adenoviral vector-based malaria vaccines
The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a p.
11/13/14
20140335118
Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (prrs)
A peptide-based marker vaccine against porcine reproductive and respiratory syndrome (prrs) and a set of immunodiagnostic tests for the prevention, monitoring and control of porcine reproductive and respiratory syndrome virus (prrsv) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from prrsv gp2, gp3, gp4, or gp5 proteins; each peptide individually contains a b cell prrsv neutralizing/receptor binding epitope which is individually linked to an artificial t helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the t helper epitopes derived from the prrsv gp4, gp5, m and nucleocapsid proteins to provide cell mediated immunity.
11/13/14
20140335116
Avoiding narcolepsy risk in influenza vaccines
The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines.. .
11/13/14
20140335112
Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
A novel form of rugged dsrna with a unique composition and physical characteristics was identified with high specificity of binding to tlr3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral ampligen® (poly i, poly c12,u) the new and improved form (poly i, poly c30,u) has a reduced tendency to form branched dsrna which results in increased bioactivity due to an increased ability to bind tlr3 receptor.
11/13/14
20140335111
Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes il-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed..
11/13/14
20140335110
Laser-based vaccine adjuvants
The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation.
11/13/14
20140335100
Therapy-enhancing glucan
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier.
11/13/14
20140335088
Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of lewy bodies and lewy neurites or is selected from the group consisting of parkinson's disease (pd), dementia with lewy bodies (dlb), the lewy body variant of alzheimer's disease, and multiple system atrophy (msa)..
11/06/14
20140329737
Development of novel macromolecule transduction domain with improved cell permeability and method for using same
The present invention relates to an improved macromolecule transduction domain (mtd), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved mtd according to the present invention, compared to an existing mtd, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like.
11/06/14
20140328880
Modified pathogens for use as vaccines
Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., yersinia pestis expressing lpxl.
11/06/14
20140328875
Influenza virus vaccines and uses thereof
Provided herein are chimeric influenza hemagglutinin (ha) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.. .
11/06/14
20140328870
Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Herpes simplex virus-2 (hsv-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against hsv-2.
10/30/14
20140323739
Compounds for preparing immunological adjuvant
And stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates..
10/30/14
20140323688
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/30/14
20140323347
Point of care immunization testing system
A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies.
10/30/14
20140322344
Vaccine preparation for cancer treatment
A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one cd8+ cytotoxic t-cell recognition epitope and at least one cd4+ helper t-cell recognition epitope.
10/30/14
20140322297
Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals
A composition comprising a drug or pharmaceutically active agent and a bioadhesive delivery system provides for the oral delivery of a vaccine to animals, particularly aquatic animals.. .
10/30/14
20140322263
Pneumococcal dosing regimen
Methods of immunizing older adult subjects against streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine.
10/30/14
20140322258
Polysaccharide-protein conjugate vaccines
Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.
10/30/14
20140322257
Fusion proteins representing different ns: proposal for a vaccine against allergy to mites
The present invention refers to recombinant dna molecules codifying fused peptides from different allergens from blomia tropicalis and dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens der p 1, der p 2, der p 7, der p 8, blo t 5, blo t 8, blo t 18, blo t 12 and blo t 13 with reduced serum ige reactivity in allergic and non allergic individuals.
10/30/14
20140322256
Vaccine candidates against johne's disease
A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, lpqp, map0834c, cspb, lipn, and map1634 of m.
10/30/14
20140322253
Cyclin a1-targeted t-cell immunotherapy for cancer
Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
10/30/14
20140322249
Dna vaccines against tumor growth and methods of use thereof
A dna vaccine suitable for eliciting an immune response against cancer cells comprises a dna construct operably encoding a cancer-associated inhibitor of apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is ccl21.
10/30/14
20140318153
Thermo-electric heat pump systems
The disclosure is directed to an energy efficient thermal protection assembly. The thermal protection assembly can comprise three or more thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
10/23/14
20140316122
Hepatitis b virus vaccines
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
10/23/14
20140316111
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyanoimidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/23/14
20140316110
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.8586

3303

2 - 1 - 71